Dr. Stephen J. Forman, MD

Dr. Forman practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Forman's NPI, 1184731135, was assigned on August 24, 2006. Dr. Forman graduated from Keck School of Medicine of USC in 1974. Dr. Forman holds California license G29700.

Dr. Forman's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Forman's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Forman to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Forman practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Forman's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Forman is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Forman's licenses on file in 3 states: California, North Carolina and Arizona.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Forman treats.

CMS data shows 774 Medicare services from Dr. Forman across 4 procedure codes in 2024, for 211 Medicare patients. Medicare paid $40,276 for them.

CMS counts 211 Medicare patients who saw Dr. Forman in 2024. The largest group is 65 to 74, with 102 patients. 72% of them have high cholesterol, and 68% have high blood pressure. 5% are also on Medicaid. Their average risk score is 2.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Forman's median patient age at 72, with 51% women.

In 2024, Dr. Forman wrote 169 Medicare Part D claims for 48 patients. 79% of them were for generic drugs. CMS names the drug for 39 of them, across 3 drugs with 11 or more claims each, at $634 in total drug cost. In 2023, CMS named 51 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Forman for performance year 2024, reported as part of a group. Dr. Forman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Forman as offering telehealth.

Dmand AI links 655 papers to Dr. Forman, published from 2003 to 2025. 2024 was the busiest year, with 37. The most frequent topics are Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation and Transplantation, Homologous. Dr. Forman has published most often in Blood. Dr. Forman's most frequent co-authors are Ryotaro Nakamura, MD, Anthony S. Stein, MD and Guido Marcucci, MD.

Dmand AI links Dr. Forman to 8 clinical trials, 4 of them phase 2 studies. Conditions studied include Agranulocytosis, Anemia, Sickle Cell and Bronchiolitis Obliterans Syndrome. Medical College of Wisconsin sponsors the most, 3.

CMS Open Payments shows 16 general payments to Dr. Forman from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $152. It also lists 3 research payments totaling $7,647 from 2016 to 2019.

Dmand AI lists 9 awards for Dr. Forman, most recently DKMS Mechtild Harf Science Award in 2019.

Dr. Forman graduated from Keck School of Medicine of USC in 1974.

Dr. Forman is in network with 7 carriers, including Blue Cross Blue Shield of Michigan, Elevance and Aetna. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.